A new study reveals how C210, a curcumin derivative, selectively reactivates Epstein–Barr virus to kill cancer cells without infectious risks, paving the way for safer, targeted cancer therapies.
McFarlan, F. Warren, Robert D. Austin, Junko Usuba, and Masako Egawa. "Secom: Managing Information Security in a Risky World." Harvard Business School Case 308-015, July 2007. (Revised April 2008.) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback